<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_bystander" title="Bystander Effects of Nitric Oxide in Cellular Models of Anti-Tumor Photodynamic Therapy" shortTitle="bystander" author="Jerzy Bazak, Witold Korytowski, Albert  W. Girotti" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6694/11/11/1674/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Clinically	RB	clinically
relevant	JJ	relevant
photodynamic	JJ	photodynamic
therapy	NN	therapy
(	-LRB-	(
PDT	NNP	PDT
)	-RRB-	)
was	VBD	be
introduced	VBN	introduce
about	RB	about
45	CD	45
years	NNS	year
ago	RB	ago
as	IN	as
a	DT	a
novel	JJ	novel
means	NN	means
for	IN	for
selectively	RB	selectively
eradicating	VBG	eradicate
a	DT	a
variety	NN	variety
of	IN	of
solid	JJ	solid
tumors	NNS	tumor
via	IN	via
cytotoxic	JJ	cytotoxic
photochemistry	NN	photochemistry
.	.	.
</s>
<s type="decl">
As	IN	as
an	DT	a
anti-tumor	JJ	anti-tumor
modality	NN	modality
,	,	,
PDT	NNP	PDT
is	VBZ	be
unique	JJ	unique
in	IN	in
requiring	VBG	require
three	CD	3
components	NNS	component
:	:	:
a	DT	a
photosensitizing	VBG	photosensizez
agent	NN	agent
(	-LRB-	(
PS	NN	PS
)	-RRB-	)
,	,	,
PS-exciting	NN	ps-exciting
light	NN	light
in	IN	in
the	DT	the
far-visible-to-near-infrared	JJ	far-visible-to-near-infrared
range	NN	range
,	,	,
and	CC	and
molecular	JJ	molecular
oxygen	NN	oxygen
.	.	.
</s>
<s type="decl">
PS	NN	PS
photoexcitation	NN	photoexcitation
during	IN	during
PDT	NNP	PDT
gives	VBZ	give
rise	NN	rise
to	IN	to
cytotoxic	JJ	cytotoxic
reactive	JJ	reactive
oxygen	NN	oxygen
species	NNS	species
(	-LRB-	(
ROS	NNS	ROS
)	-RRB-	)
such	JJ	such
as	IN	as
singlet	NN	singlet
oxygen	NN	oxygen
(	-LRB-	(
1O2	CD	1O2
)	-RRB-	)
.	.	.
</s>
<s type="decl">
The	DT	the
first	JJ	first
PS	NNS	PS
to	TO	to
receive	VB	receive
FDA	NNP	FDA
approval	NN	approval
for	IN	for
PDT	NNP	PDT
applications	NNS	application
was	VBD	be
Photofrin®	NNP	Photofrin®
,	,	,
an	DT	a
oligomeric	JJ	oligomeric
form	NN	form
of	IN	of
hematoporphyrin	NN	hematoporphyrin
that	WDT	that
continues	VBZ	continue
to	TO	to
be	VB	be
used	VBN	use
for	IN	for
a	DT	a
variety	NN	variety
of	IN	of
malignancies	NNS	malignancy
.	.	.
</s>
<s type="decl">
Unlike	IN	unlike
more	RBR	more
conventional	JJ	conventional
chemotherapy	NN	chemotherapy
or	CC	or
radiotherapy	NN	radiotherapy
,	,	,
PDT	NNP	PDT
has	VBZ	have
few	JJ	few
(	-LRB-	(
if	IN	if
any	DT	any
)	-RRB-	)
light-independent	JJ	light-independent
side	NN	side
effects	NNS	effect
and	CC	and
is	VBZ	be
non-invasive	JJ	non-invasive
and	CC	and
site-specific	JJ	site-specific
,	,	,
i.e.	FW	i.e.
,	,	,
limited	VBN	limit
to	IN	to
the	DT	the
tumor	NN	tumor
upon	IN	upon
which	WDT	which
light	NN	light
is	VBZ	be
directed	VBN	direct
,	,	,
typically	RB	typically
via	IN	via
fiber	NN	fiber
optic	JJ	optic
networks	NNS	network
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
PDT	NNP	PDT
can	MD	can
often	RB	often
overcome	VB	overcome
the	DT	the
innate	JJ	innate
or	CC	or
acquired	VBN	acquire
resistance	NN	resistance
to	IN	to
other	JJ	other
therapies	NNS	therapy
that	WDT	that
many	JJ	many
tumors	NNS	tumor
exhibit	VBP	exhibit
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
to	IN	to
pre-existing	JJ	pre-exist
administered	VBN	administer
sensitizers	NNS	sensitizer
such	JJ	such
as	IN	as
Photofrin®	NNP	Photofrin®
,	,	,
pro-sensitizers	NNS	pro-sensitizer
have	VBP	have
been	VBN	be
developed	VBN	develop
,	,	,
one	CD	one
common	JJ	common
example	NN	example
being	VBG	be
5-aminolevulinic	JJ	5-aminolevulinic
acid	NN	acid
(	-LRB-	(
ALA	NNP	ALA
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Upon	IN	upon
entering	VBG	enter
cancer	NN	cancer
cells	NNS	cell
via	IN	via
an	DT	a
amino	NN	amino
acid	NN	acid
transporter	NN	transporter
,	,	,
ALA	NNP	ALA
is	VBZ	be
metabolized	VBN	metabolize
to	IN	to
protoporphyrin	NN	protoporphyrin
IX	CD	ix
(	-LRB-	(
PpIX	NNP	PpIX
)	-RRB-	)
,	,	,
the	DT	the
active	JJ	active
PS	NN	PS
,	,	,
via	IN	via
the	DT	the
heme	NN	heme
biosynthetic	JJ	biosynthetic
pathway	NN	pathway
,	,	,
PpIX	NNP	PpIX
accumulating	VBG	accumulate
initially	RB	initially
in	IN	in
mitochondria	NNS	mitochondria
.	.	.
</s>
<s type="decl">
For	IN	for
rapid	JJ	rapid
proliferative	JJ	proliferative
needs	NNS	need
,	,	,
tumor	NN	tumor
cells	NNS	cell
are	VBP	be
more	RBR	more
active	JJ	active
in	IN	in
heme	NN	heme
synthesis	NN	synthesis
than	IN	than
normal	JJ	normal
counterparts	NNS	counterpart
.	.	.
</s>
<s type="sub">
In	IN	in
addition	NN	addition
to	IN	to
acting	VBG	act
as	IN	as
a	DT	a
PDT	NNP	PDT
sensitizer	NN	sensitizer
,	,	,
ALA-induced	NNP	ALA-induced
PpIX	NN	PpIX
,	,	,
like	IN	like
that	DT	that
induced	VBN	induce
by	IN	by
more	RBR	more
lipophilic	JJ	lipophilic
ALA	NNP	ALA
esters	NNS	ester
,	,	,
e.g.	FW	e.g.
,	,	,
Hexvix	NNP	Hexvix
,	,	,
can	MD	can
serve	VB	serve
as	IN	as
a	DT	a
highly	RB	highly
effective	JJ	effective
fluorophore	NN	fluorophore
for	IN	for
image-guided	JJ	image-guided
tumor	NN	tumor
resection	NN	resection
.	.	.
</s>
<s type="decl">
Many	JJ	many
cancer	NN	cancer
cells	NNS	cell
exhibit	VBP	exhibit
an	DT	a
intrinsic	JJ	intrinsic
or	CC	or
acquired	VBN	acquire
resistance	NN	resistance
to	IN	to
radiotherapy	NN	radiotherapy
or	CC	or
chemotherapy	NN	chemotherapy
,	,	,
and	CC	and
resistance	NN	resistance
to	IN	to
PDT	NNP	PDT
has	VBZ	have
also	RB	also
been	VBN	be
demonstrated	VBN	demonstrate
.	.	.
</s>
<s type="decl">
For	IN	for
ALA-PDT	NNP	ALA-PDT
,	,	,
one	CD	one
notable	JJ	notable
resistance	NN	resistance
mechanism	NN	mechanism
involves	VBZ	involve
efflux	NN	efflux
of	IN	of
newly	RB	newly
synthesized	VBN	synthesize
PpIX	NN	PpIX
via	IN	via
the	DT	the
plasma	NN	plasma
membrane	NN	membrane
transporter	NN	transporter
ABCG2	NNP	ABCG2
.	.	.
</s>
<s type="decl">
Another	DT	another
important	JJ	important
mechanism	NN	mechanism
involves	VBZ	involve
nitric	NN	nitric
oxide	NN	oxide
(	-LRB-	(
NO	NNP	NO
)	-RRB-	)
generated	VBN	generate
by	IN	by
constitutive	JJ	constitutive
and/or	NN	and/or
PDT	NNP	PDT
stress-upregulated	NN	stress-upregulated
inducible	NN	inducible
nitric	NN	nitric
oxide	NN	oxide
synthase	NN	synthase
(	-LRB-	(
iNOS/NOS2	NNP	iNOS/NOS2
)	-RRB-	)
.	.	.
</s>
</p>
<p>
<s type="decl">
NO	NN	no
is	VBZ	be
a	DT	a
bioactive	JJ	bioactive
free	JJ	free
radical	JJ	radical
molecule	NN	molecule
(	-LRB-	(
1	CD	1
–	SYM	-
2	CD	2
sec	NN	sec
lifetime	NN	lifetime
in	IN	in
water	NN	water
)	-RRB-	)
that	WDT	that
diffuses	VBZ	diffus
freely	RB	freely
on	IN	on
its	PRP$	its
own	JJ	own
and	CC	and
,	,	,
similar	JJ	similar
to	IN	to
oxygen	NN	oxygen
(	-LRB-	(
O2	NN	O2
)	-RRB-	)
,	,	,
tends	VBZ	tend
to	TO	to
partition	VB	partition
into	IN	into
hydrophobic	JJ	hydrophobic
regions	NNS	region
of	IN	of
cells	NNS	cell
,	,	,
e.g.	FW	e.g.
,	,	,
cell	NN	cell
membranes	NNS	membrane
.	.	.
</s>
<s type="decl">
At	IN	at
relatively	RB	relatively
low	JJ	low
steady	JJ	steady
state	NN	state
levels	NNS	level
(	-LRB-	(
e.g.	FW	e.g.
,	,	,
50	CD	50
–	SYM	-
300	CD	300
nM	NN	nM
range	NN	range
)	-RRB-	)
,	,	,
NO	NN	no
is	VBZ	be
known	VBN	know
to	TO	to
play	VB	play
a	DT	a
key	JJ	key
signaling	VBG	signal
role	NN	role
in	IN	in
survival	NN	survival
,	,	,
migration	NN	migration
,	,	,
and	CC	and
drug	NN	drug
resistance	NN	resistance
of	IN	of
many	JJ	many
different	JJ	different
cancer	NN	cancer
cells	NNS	cell
.	.	.
</s>
<s type="decl">
This	DT	this
contrasts	VBZ	contrast
with	IN	with
the	DT	the
cytotoxic	JJ	cytotoxic
effects	NNS	effect
of	IN	of
NO	NN	no
produced	VBN	produce
at	IN	at
much	RB	much
higher	JJR	high
levels	NNS	level
(	-LRB-	(
≥1	NN	≥1
µM	NN	µM
)	-RRB-	)
by	IN	by
activated	VBN	activate
macrophages	NNS	macrophage
during	IN	during
an	DT	a
inflammatory	JJ	inflammatory
response	NN	response
,	,	,
e.g.	FW	e.g.
,	,	,
to	IN	to
infection	NN	infection
.	.	.
</s>
<s type="decl">
In	IN	in
previous	JJ	previous
work	NN	work
,	,	,
we	PRP	we
discovered	VBD	discover
that	IN	that
various	JJ	various
cancer	NN	cancer
cell	NN	cell
lines	NNS	line
significantly	RB	significantly
upregulate	VBP	upregulate
cytoprotective	JJ	cytoprotective
iNOS	NN	iNOS
and	CC	and
NO	NN	no
after	IN	after
a	DT	a
moderate	JJ	moderate
photodynamic	JJ	photodynamic
challenge	NN	challenge
sensitized	VBN	sensitize
by	IN	by
ALA-induced	NNP	AlA-induce
PpIX	NNP	PpIX
.	.	.
</s>
<s type="decl">
The	DT	the
iNOS/NO	NN	inos/no
induction	NN	induction
in	IN	in
PDT-surviving	VBG	pDT-survive
(	-LRB-	(
still	RB	still
attached	VBN	attach
)	-RRB-	)
cells	NNS	cell
was	VBD	be
relatively	RB	relatively
rapid	JJ	rapid
after	IN	after
irradiation	NN	irradiation
(	-LRB-	(
2	CD	2
–	SYM	-
3	CD	3
h	NN	hour
)	-RRB-	)
and	CC	and
prolonged	VBN	prolong
(	-LRB-	(
at	IN	at
least	JJS	least
24	CD	24
h	NN	hour
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Importantly	RB	importantly
,	,	,
these	DT	this
cells	NNS	cell
exhibited	VBD	exhibit
a	DT	a
more	RBR	more
aggressive	JJ	aggressive
growth	NN	growth
,	,	,
migratory	JJ	migratory
,	,	,
and	CC	and
invasive	JJ	invasive
phenotype	NN	phenotype
than	IN	than
non-photostressed	JJ	non-photostressed
controls	NNS	control
,	,	,
and	CC	and
this	DT	this
was	VBD	be
suppressed	VBN	suppress
by	IN	by
inhibition	NN	inhibition
of	IN	of
iNOS	NN	iNOS
or	CC	or
by	IN	by
NO	DT	no
scavenging	NN	scavenging
.	.	.
</s>
<s type="decl">
We	PRP	we
postulated	VBD	postulate
that	IN	that
induced	VBN	induce
diffusible	JJ	diffusible
NO	NN	no
from	IN	from
PDT-targeted	VBN	pDT-targe
cells	NNS	cell
might	MD	might
elicit	VB	elicit
a	DT	a
pro-growth/migratory	JJ	pro-growth/migratory
response	NN	response
in	IN	in
non-	JJ	non-
or	CC	or
minimally-targeted	JJ	minimally-targeted
bystander	NN	bystander
cells	NNS	cell
.	.	.
</s>
<s type="sub">
In	IN	in
an	DT	a
actual	JJ	actual
tumor	NN	tumor
,	,	,
such	JJ	such
targeting	NN	targeting
diversity	NN	diversity
might	MD	might
result	VB	result
from	IN	from
uneven	JJ	uneven
PS	NN	PS
distribution	NN	distribution
due	JJ	due
to	IN	to
irregularities	NNS	irregularity
in	IN	in
the	DT	the
tumor	NN	tumor
microvasculature	NN	microvasculature
.	.	.
</s>
<s type="decl">
Using	VBG	use
photosensitized	VBN	photosensitize
prostate	NN	prostate
cancer	NN	cancer
PC3	NN	PC3
cells	NNS	cell
,	,	,
we	PRP	we
recently	RB	recently
observed	VBD	observe
NO-mediated	VBN	no-mediate
hyper-aggressive	JJ	hyper-aggressive
bystander	NN	bystander
effects	NNS	effect
for	IN	for
the	DT	the
first	JJ	first
time	NN	time
in	IN	in
the	DT	the
context	NN	context
of	IN	of
PDT	NNP	PDT
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
present	JJ	present
study	NN	study
,	,	,
we	PRP	we
compared	VBD	compare
the	DT	the
ability	NN	ability
of	IN	of
four	CD	4
PDT-treated	JJ	PDT-treated
cancer	NN	cancer
lines	NNS	line
(	-LRB-	(
melanoma	NN	melanoma
BLM	NNP	BLM
,	,	,
glioblastoma	NN	glioblastoma
U87	NNP	U87
,	,	,
breast	NN	breast
MDA-MB-231	NNP	MDA-MB-231
,	,	,
and	CC	and
prostate	NN	prostate
PC3	NNP	PC3
)	-RRB-	)
to	TO	to
stimulate	VB	stimulate
NO-dependent	JJ	NO-dependent
aggressiveness	NN	aggressiveness
in	IN	in
bystander	NN	bystander
cells	NNS	cell
of	IN	of
the	DT	the
same	JJ	same
type	NN	type
.	.	.
</s>
</p>
</text>